ClinicalTrials.gg
CompletedNCT06300996Updated Oct 23, 2026

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

An interventional study of Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) in Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3 and Spinal Muscular Atrophy Type II, sponsored by Marco Capogrosso. Completed at 1 site in United States. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionSpinal Muscular Atrophies of ChildhoodRegistry: Muscular Atrophy, SpinalReclassifiedWhy we changed it
Registry
Muscular Atrophy, Spinal — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spinal Muscular Atrophies of Childhood
Why
  1. The study's listed conditions name Spinal Muscular Atrophies of Childhood, a narrower term within Muscular Atrophy, Spinal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Marco Capogrosso · Not applicable, Interventional, and Basic science

How we know

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
16 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States — 3 open to participants now, 7 under way, 2 of them phase 3. Spinal Muscular Atrophies of Childhood · United States.

Enrollment
12th of 13
3 · median 40
Started
2024
with 1 other
No phase
3 of 23
none open now
Registered
19th of 23
by date
Lead sponsor
2 of 23
Marco Capogrosso

Among the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 with no phase, and was the 19th registered.

Spinal Muscular Atrophies of Childhood

61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.

Browse Spinal Muscular Atrophies of Childhood studies →

Open to participants now

3 of the 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Spinal Muscular Atrophies of Childhood studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 16 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Spinal Muscular Atrophies of Childhood with a site in United States, or all of them as a file.
02

Study summary

Spinal cord stimulation (SCS) has shown remarkable efficacy in restoring motor function in people with spinal cord injury by recruiting afferent input to enhance the responsiveness of spared neural circuits to residual cortical inputs. This pilot will test if SCS can show evidence to improve motor deficits in people with Type 2, 3, or 4 spinal muscular atrophy (SMA). The investigators will enroll up to six subjects with Type 2, 3, or 4 SMA aged 16 or older that show quantifiable motor deficits of the upper body. The investigators will then implant the subjects with percutaneous, linear spinal leads near the cervical spinal cord for a period of up to 29 days. Although these leads are not optimized for motor function but rather for their clinically approved indication of treating pain, the investigators believe they provide a safe technology enabling our team to perform scientific measurement necessary to evaluate potential for effects of SCS in motor paralysis with SMA. After the end of the study, the leads will be explanted.

Read the detailed description

The investigators plan to 1. verify that spinal cord stimulation increases elbow muscle strength in subjects with SMA, 2. verify that spinal cord stimulation improves motor control in subjects with SMA, 3. verify that spinal cord stimulation induces measurable changes in spinal circuits and motoneuron recruitment properties in the 29 day course of implantation.

03

Conditions studied

  • Spinal Muscular Atrophy
  • Spinal Muscular Atrophy Type 3
  • Spinal Muscular Atrophy Type II
  • Spinal Muscular Atrophy 4
  • SMA

Browse trials for

Keywords

  • Spinal Cord Stimulation
04

In context

Spinal Muscular Atrophies of Childhood Reclassified

61 studies on the registry are indexed under Spinal Muscular Atrophies of Childhood; 18 are open to participants now.

This study's enrollment of 3 is below the median of 15 across 41 interventional studies indexed under Spinal Muscular Atrophies of Childhood.

Browse Spinal Muscular Atrophies of Childhood studies →

Lead sponsor

Marco Capogrosso is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Spinal Muscular Atrophies of Childhood, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Muscular Atrophy, Spinal. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

SMA Participant Inclusion Criteria:

  1. Subject has a diagnosis of 5q-autosomal recessive SMA confirmed by determination of a genetic deletion in the SMN1 gene (5q12.2-q13.3).
  2. Subject is diagnosed as being non-ambulatory SMA based on the following criteria:

    a. Can't stand independently.

  3. Subject is ≥16 years of age and \< 65 years of age.
  4. Subject is able to sit independently.
  5. A minimum score of 1 for Entry Item "A" of the Revised Upper Limb Module (RULM) scale for SMA: "Can use hands to hold pencil or pick up a coin/token or drive a powered chair, use phone key pad"
  6. Subject (and subject's parent or legal guardian if subject is a minor) is willing and able to comply with scheduled visits and study procedures
  7. Participants must have started SMN inducing therapies (Spinraza or risdisplam) at least 6 months prior to enrollment. (They must have either gotten their first injection at at least 6 months prior, or they started daily intake of risdisplam at least 6 months prior to the study)

Healthy Control Participant Inclusion Criteria:

  1. Subject is ≥18 years of age and \< 65 years of age.
  2. Subject is able to stand independently for ≥3 seconds.
  3. Subject is willing and able to comply with scheduled visits and study procedures.

SMA Participant Exclusion Criteria:

  1. Subject has deformation of the spinal canal preventing lead implantation as judged by the study neurosurgeon
  2. Subject has size of spinal canal that is insufficient for lead implantation as judged by the study neurosurgeon
  3. Subject has moderate or severe joint contractures that would affect ability to perform study measures, determined by the study physician
  4. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator
  5. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety of anesthesia or the procedures, make it unlikely that intervention or follow-up will be correctly completed or impair the assessment of study results, in the opinion of the investigator
  6. Female subjects are pregnant or breastfeeding, as established by self-report.
  7. Subject has severe claustrophobia
  8. Subject is on anticoagulant, anti-spasticity or anti-seizure medication within 4 weeks of lead implantation or requires these medications during the treatment phase of the study
  9. Subject has medical implant that precludes magnetic resonance imaging
  10. Subject has a deconditioned respiratory system, per the discretion of the physician investigator.
  11. Subjects with renal insufficiency at the discretion of the physician investigator.
  12. Subjects requiring any form of sedation for MRI will be excluded.

Healthy Control Participant Exclusion Criteria:

  1. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator would impact participation in the study.
  2. Participants who have any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, neurological conditions other than stroke, etc.) or cognitive impairments that could affect their ability to participate in this study.
  3. Female subjects are pregnant or breastfeeding, as established by self-report.
  4. Subjects requiring sedation for MRI will be excluded.
06

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Spinal Cord Stimulation

    All patients will receive FDA-approved percutaneous spinal cord stimulation leads implanted in the cervical epidural (C4-T1 vertebra) space. The leads will be connected to external stimulators (either FDA-approved or human-grade research stimulator with safety features) during research activities.

    Device: Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)

Interventions

  • DeviceSpinal Cord Stimulator (Octopolar Medtronic Vectris Leads)

    Spinal cord stimulation is FDA approved for treatment of pain. We are proposing utilizing the same technology to help restore motor control in people who have declining function due to the progression of SMA. These are 2-4 leads that are FDA-approved.

07

What researchers measure

Primary outcomes

  1. Number and Severity of Adverse Events

    Success Criteria: no serious adverse events related to the stimulation or intolerable. adverse events reported

    Time frame: 29 days

Secondary outcomes

  1. Muscle Weakness Muscle Activation

    Muscle activation: measure surface electromyogram (EMGs) produced by the subjects during isometric movements of the elbow in the HUMAC Norm and compare to SCS-on with SCS-off and non-affected SCS side performances. Meaningful Change: \>20% EMG root-mean-square (RMS) compared to SCS-on.

    Time frame: 29 days

  2. Motor Function ROM

    Range of Motion (ROM): Meaningful Change: Increase of \>20% of the elbow joint (if available) during SCS-on against SCS-off and SCS-non affected arm as measured by the HUMAC Norm during single-joint isotonic trials.

    Time frame: 29 days

  3. Motor Function RULM

    The Revised Upper Limb Module (RULM) for SMA is a further refined version of the Hammersmith Functional Motor Scale Extended and includes specific items focused on upper-limb motor control such as raising the arms above the head that are particularly relevant for the Type 2 population of the study, or those with further progressed Type 3 and Type 4. The scale is a performance evaluation with a total score ranging from 0, if none of the activities is achieved, to 37, if all the activities are achieved fully, so a higher score means a better outcome. For our study, we require participants to score at least a 4 to be eligible. Meaningful Change: ≥2 point improvement. Compare outcomes between SCS-on and SCS-off as well as the non-affected arm.

    Time frame: 29 days

  4. Motor Function Fatigue

    Fatigue will be assessed during motor function tests. Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of fatigue for each stimulation configuration.

    Time frame: 29 days

  5. Discomfort/Pain

    Patients will be asked to provide a score from 1-10, where a greater number indicates a greater amount of discomfort for each stimulation configuration. Spinal cord stimulation produces tingling sensations and other type of sensory phenomena. It is important to document that stimulation intensities required to improve motor function remain within a range of non-painful sensations.

    Time frame: 29 days

  6. Sensorimotor Network Structure Density

    The investigators will perform high-definition weighted imaging to quantify fractional anisotropy as a measurement of axon density in the brain and spinal cord pre and post study.

    Time frame: 29 days

  7. Impression

    The investigators will collect subjects and therapist feedback on how the technology is performing and what they would want to modify using The Clinical Global Impression Scale, a scale of 1-7 where a lower number indicates better performance and a higher number indicates more greatly impacted by their disease.

    Time frame: 29 days

  8. Sensorimotor Network Structure Integrity

    The investigators will perform high-definition diffusion weighted imaging to quantify fractional anisotropy as a measurement of axon integrity in the brain and spinal cord pre and post study.

    Time frame: 29 days

  9. Sensorimotor Network Function

    The investigators will perform resting state and motor-task functional MRI of the brain and spinal cord to quantify neural network activation at rest and during the execution of simple motor task such as leg muscle contraction.

    Time frame: 29 days

  10. Cortico-spinal Tract Integrity

    The investigators will measure muscle evoked potential consequent to Transcranial Magnetic Stimulation of the cortico-spinal tract to assess the integrity of the cortico-spinal tract.

    Time frame: 29 days

  11. Spinal Circuit Excitability

    The investigators will measure H-reflexes of the arm muscles to quantify excitability of spinal motoneurons to stimulation of primary sensory afferents pre and post-study. Expected Result: Our main scientific hypothesis is that SCS will restore monosynaptic responses of weak spinal motoneurons, thus increasing H-reflex responses pre and post study.

    Time frame: 29 days

  12. Motoneuron Firing Rates

    The investigators will use high-density EMGs on leg muscles to calculate firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.

    Time frame: 29 days

  13. Motor Firing Number

    The investigators will use high-density EMGs on arm muscles to calculate the number of firing rates of single spinal motoneuron discharge during isometric maximal voluntary contractions.

    Time frame: 29 days

  14. Muscle Weakness Torque

    Isometric torque: measure the isometric torque produced by the subject at the elbow during flexion and extension as well as grip function during hand held dynamometer as well as during wrist flexion and extension. The investigators will use the measurement of isometric torque to determine the changes in muscle strength for each participant with SCS on and with SCS off. This comparison will also include testing the non-affected arm to give the investigators a baseline for normal movement of the joint being tested. Success Criteria: ≥30% increased torque production over the SCS-off/non-affected baseline as measured during single-joint isometric torque.

    Time frame: 29 days

08

Study locations

1 site
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, may be shared with other researchers for the purpose of data analysis and collaboration.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will become available at the end of the trial upon publication of the first manuscript. Estimation is 2 years from enrollment of first participant.

Access criteria: Data must be directly requested to the PI and will be shared upon completion of necessary data sharing agreement to protect confidential patient information.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Oct 2026, 28 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2029 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 8, 2024
StartActual
May 31, 2024
Primary completionActual
Oct 19, 2026was Sep 2026
CompletionActual
Oct 19, 2026was Sep 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Primary completion
Sep 2026→Oct 19, 2026 (actual)
Oct 23, 2026
Study completion
Sep 2029→Oct 19, 2026 (actual)
Oct 23, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedMuscle Weakness TorqueTime frame: 29 days
Oct 23, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedMuscle Weakness TorqueTime frame: 29 days
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Primary completion Sep 2026→Oct 19, 2026 (now actual)
    Study completion Sep 2029→Oct 19, 2026 (now actual)
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedMuscle Weakness TorqueTime frame: 29 days
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedMuscle Weakness TorqueTime frame: 29 days
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06300996
Lead sponsor
Marco Capogrosso
Collaborators
Roche-Genentech
Responsible party
Marco Capogrosso (Assistant Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Mar 8, 2024
Start date
May 31, 2024
Primary completion
Oct 19, 2026
Completion
Oct 19, 2026
Last update
Oct 23, 2026

Study contacts

Marco Capogrosso
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion